New pill plus immunotherapy shows promise for liver cancer

NCT ID NCT06680258

Not yet recruiting Disease control Sponsor: Tempest Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 3 trial tests whether adding an experimental drug (TPST-1120) to standard immunotherapy and anti-angiogenic therapy helps people with advanced liver cancer live longer. About 740 adults whose cancer cannot be surgically removed or has spread will be randomly assigned to receive either the new combo or a placebo plus standard care. The study will also check safety and tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TPST-1120 (a drug taken by mouth) combined with atezolizumab and bevacizumab (both given by IV)
What this could lead to: If successful, this combination could become a new standard treatment for advanced liver cancer, helping patients live longer and slowing cancer growth.
What could go wrong: This is a phase 3 trial, but it's still experimental. The added drug may not improve outcomes over current therapy, and side effects could be more severe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma Liver Neoplasms Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA (HCC)

More trials for these conditions

Other studies related to the condition(s) this trial covers.